A look back at post hoc analysis

A look back at post hoc analysis By Lesley Fair People who claim that hindsight is 20/20 probably weren't talking about the post hoc evaluation of clinical testing. That's an alleged flaw the FTC challenged in purported substantiation submitted by the marketers of Hepaxa and Hepaxa PD, fish oil products advertised as clinically proven to treat liver disease in adults and children. In addition to injunctive provisions, the proposed settlement includes a financial remedy of $416,914. Read more > SUBSCRIBER SERVICES:  Manage Preferences  |  Unsubscribe  |  Help This is a free service provided by the Federal Trade Commission

---

This email was sent to jtrent238.test@blogger.com using GovDelivery Communications Cloud on behalf of: FTC Business Alerts · 600 Pennsylvania Ave., NW · Washington, DC 20580 · 1-877-382-4357